Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US Acute Agitation Aggression Treatment Market

ID: MRFR/Pharma/15218-HCR
100 Pages
Vikita Thakur
Last Updated: April 06, 2026

US Acute Agitation Aggression Treatment Market Research Report: Size, Share, Trend Analysis By Drug Class (First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Others), By Route of Administration (Oral, Intramuscular, Others), By Indication (Schizophrenia, Dementia, Bipolar Disorder, Depression, Drug-induced Agitation and Aggression, Alcohol Withdrawal, Others) and By End Users (Hospitals & Clinics, Psychiatric Care Facilities, Others) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Acute Agitation Aggression Treatment Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Drug Class (USD Million)
  49.     4.1.1 First-Generation Anti-Psychotics
  50.     4.1.2 Second-Generation Anti-Psychotics
  51.     4.1.3 Benzodiazepines
  52.     4.1.4 Others
  53.   4.2 Healthcare, BY Route of Administration (USD Million)
  54.     4.2.1 Oral
  55.     4.2.2 Intramuscular
  56.     4.2.3 Others
  57.   4.3 Healthcare, BY Indication (USD Million)
  58.     4.3.1 Schizophrenia
  59.     4.3.2 Dementia
  60.     4.3.3 Bipolar Disorder
  61.     4.3.4 Depression
  62.     4.3.5 Drug-induced Agitation and Aggression
  63.     4.3.6 Alcohol Withdrawal
  64.     4.3.7 Others
  65.   4.4 Healthcare, BY End User (USD Million)
  66.     4.4.1 Hospitals & Clinics
  67.     4.4.2 Psychiatric Care Facilities
  68.     4.4.3 Others
  69. 5 SECTION V: COMPETITIVE ANALYSIS
  70.   5.1 Competitive Landscape
  71.     5.1.1 Overview
  72.     5.1.2 Competitive Analysis
  73.     5.1.3 Market share Analysis
  74.     5.1.4 Major Growth Strategy in the Healthcare
  75.     5.1.5 Competitive Benchmarking
  76.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  77.     5.1.7 Key developments and growth strategies
  78.       5.1.7.1 New Product Launch/Service Deployment
  79.       5.1.7.2 Merger & Acquisitions
  80.       5.1.7.3 Joint Ventures
  81.     5.1.8 Major Players Financial Matrix
  82.       5.1.8.1 Sales and Operating Income
  83.       5.1.8.2 Major Players R&D Expenditure. 2023
  84.   5.2 Company Profiles
  85.     5.2.1 Johnson & Johnson (US)
  86.       5.2.1.1 Financial Overview
  87.       5.2.1.2 Products Offered
  88.       5.2.1.3 Key Developments
  89.       5.2.1.4 SWOT Analysis
  90.       5.2.1.5 Key Strategies
  91.     5.2.2 Pfizer Inc (US)
  92.       5.2.2.1 Financial Overview
  93.       5.2.2.2 Products Offered
  94.       5.2.2.3 Key Developments
  95.       5.2.2.4 SWOT Analysis
  96.       5.2.2.5 Key Strategies
  97.     5.2.3 Bristol-Myers Squibb (US)
  98.       5.2.3.1 Financial Overview
  99.       5.2.3.2 Products Offered
  100.       5.2.3.3 Key Developments
  101.       5.2.3.4 SWOT Analysis
  102.       5.2.3.5 Key Strategies
  103.     5.2.4 Eli Lilly and Company (US)
  104.       5.2.4.1 Financial Overview
  105.       5.2.4.2 Products Offered
  106.       5.2.4.3 Key Developments
  107.       5.2.4.4 SWOT Analysis
  108.       5.2.4.5 Key Strategies
  109.     5.2.5 AstraZeneca (GB)
  110.       5.2.5.1 Financial Overview
  111.       5.2.5.2 Products Offered
  112.       5.2.5.3 Key Developments
  113.       5.2.5.4 SWOT Analysis
  114.       5.2.5.5 Key Strategies
  115.     5.2.6 Roche Holding AG (CH)
  116.       5.2.6.1 Financial Overview
  117.       5.2.6.2 Products Offered
  118.       5.2.6.3 Key Developments
  119.       5.2.6.4 SWOT Analysis
  120.       5.2.6.5 Key Strategies
  121.     5.2.7 Novartis AG (CH)
  122.       5.2.7.1 Financial Overview
  123.       5.2.7.2 Products Offered
  124.       5.2.7.3 Key Developments
  125.       5.2.7.4 SWOT Analysis
  126.       5.2.7.5 Key Strategies
  127.     5.2.8 Otsuka Pharmaceutical Co Ltd (JP)
  128.       5.2.8.1 Financial Overview
  129.       5.2.8.2 Products Offered
  130.       5.2.8.3 Key Developments
  131.       5.2.8.4 SWOT Analysis
  132.       5.2.8.5 Key Strategies
  133.   5.3 Appendix
  134.     5.3.1 References
  135.     5.3.2 Related Reports
  136. 6 LIST OF FIGURES
  137.   6.1 MARKET SYNOPSIS
  138.   6.2 US MARKET ANALYSIS BY DRUG CLASS
  139.   6.3 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  140.   6.4 US MARKET ANALYSIS BY INDICATION
  141.   6.5 US MARKET ANALYSIS BY END USER
  142.   6.6 KEY BUYING CRITERIA OF HEALTHCARE
  143.   6.7 RESEARCH PROCESS OF MRFR
  144.   6.8 DRO ANALYSIS OF HEALTHCARE
  145.   6.9 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  146.   6.10 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  147.   6.11 SUPPLY / VALUE CHAIN: HEALTHCARE
  148.   6.12 HEALTHCARE, BY DRUG CLASS, 2024 (% SHARE)
  149.   6.13 HEALTHCARE, BY DRUG CLASS, 2024 TO 2035 (USD Million)
  150.   6.14 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
  151.   6.15 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
  152.   6.16 HEALTHCARE, BY INDICATION, 2024 (% SHARE)
  153.   6.17 HEALTHCARE, BY INDICATION, 2024 TO 2035 (USD Million)
  154.   6.18 HEALTHCARE, BY END USER, 2024 (% SHARE)
  155.   6.19 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Million)
  156.   6.20 BENCHMARKING OF MAJOR COMPETITORS
  157. 7 LIST OF TABLES
  158.   7.1 LIST OF ASSUMPTIONS
  159.     7.1.1
  160.   7.2 US MARKET SIZE ESTIMATES; FORECAST
  161.     7.2.1 BY DRUG CLASS, 2025-2035 (USD Million)
  162.     7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  163.     7.2.3 BY INDICATION, 2025-2035 (USD Million)
  164.     7.2.4 BY END USER, 2025-2035 (USD Million)
  165.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  166.     7.3.1
  167.   7.4 ACQUISITION/PARTNERSHIP
  168.     7.4.1

US Healthcare Market Segmentation

Healthcare By Drug Class (USD Million, 2025-2035)

  • First-Generation Anti-Psychotics
  • Second-Generation Anti-Psychotics
  • Benzodiazepines
  • Others

Healthcare By Route of Administration (USD Million, 2025-2035)

  • Oral
  • Intramuscular
  • Others

Healthcare By Indication (USD Million, 2025-2035)

  • Schizophrenia
  • Dementia
  • Bipolar Disorder
  • Depression
  • Drug-induced Agitation and Aggression
  • Alcohol Withdrawal
  • Others

Healthcare By End User (USD Million, 2025-2035)

  • Hospitals & Clinics
  • Psychiatric Care Facilities
  • Others

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓